Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepa Jagadeesh

Showing results (11-20 of 93) with videos related to

Pageof 10
Sort By:
Oxford Medical Case Reports|December 13, 2018
Corrigendum to: Post-transplant lymphoproliferative disorder presenting on post-transplant Day 35 as a pulmonary parenchymal infiltrate-a case reportAndrew J Lewis, Deepa Jagadeesh, Sanjay Mukhopadhyay, et al.
Orbit (Amsterdam, Netherlands)|July 19, 2017
Orbital diffuse large B-cell lymphoma with combined variable immunodeficiencyVishal S Parikh, Deepa Jagadeesh, James M Fernandez, et al.
American Journal of Hematology|June 15, 2017
Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphomaCaner Saygin, Xuefei Jia, Brian Hill, et al.
Ejhaem|January 29, 2025
Angioimmunoblastic T-cell lymphoma: Characterization of clonal T and B cells and a patient-derived xenograft study of coexisting T- and B-cell proliferationXiaoxian Zhao, Deepa Jagadeesh, Juraj Bodo, et al.
Cancer|December 13, 2005
Detection of stool DNA mutations before and after treatment of colorectal neoplasiaSapna Syngal, Elena Stoffel, Daniel Chung, et al.
British Journal of Haematology|May 3, 2016
Is rituximab sub-optimally dosed in indolent B cell lymphoma?Yazeed Sawalha, Basel Rouphail, Xuefei Jia, et al.
Leukemia & Lymphoma|March 8, 2024
Lenalidomide, rituximab (R<sup>2</sup>), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphomaBrian T Hill, Yanwen Chen, Deepa Jagadeesh, et al.
Hematological Oncology|June 13, 2023
A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapiesRahul Mishra, Danai Dima, Sumukh A Kumar, et al.
Leukemia & Lymphoma|September 15, 2021
The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphomaYazeed Sawalha, Tomas Radivoyevitch, Xuefei Jia, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2017
Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General PopulationYazan F Madanat, Lisa Rybicki, Tomas Radivoyevitch, et al.
Pageof 10

Showing results (11-20 of 93) with videos related to

Sort By:
Pageof 10
Oxford Medical Case Reports|December 13, 2018
Corrigendum to: Post-transplant lymphoproliferative disorder presenting on post-transplant Day 35 as a pulmonary parenchymal infiltrate-a case reportAndrew J Lewis, Deepa Jagadeesh, Sanjay Mukhopadhyay, et al.
Orbit (Amsterdam, Netherlands)|July 19, 2017
Orbital diffuse large B-cell lymphoma with combined variable immunodeficiencyVishal S Parikh, Deepa Jagadeesh, James M Fernandez, et al.
American Journal of Hematology|June 15, 2017
Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphomaCaner Saygin, Xuefei Jia, Brian Hill, et al.
Ejhaem|January 29, 2025
Angioimmunoblastic T-cell lymphoma: Characterization of clonal T and B cells and a patient-derived xenograft study of coexisting T- and B-cell proliferationXiaoxian Zhao, Deepa Jagadeesh, Juraj Bodo, et al.
Cancer|December 13, 2005
Detection of stool DNA mutations before and after treatment of colorectal neoplasiaSapna Syngal, Elena Stoffel, Daniel Chung, et al.
British Journal of Haematology|May 3, 2016
Is rituximab sub-optimally dosed in indolent B cell lymphoma?Yazeed Sawalha, Basel Rouphail, Xuefei Jia, et al.
Leukemia & Lymphoma|March 8, 2024
Lenalidomide, rituximab (R<sup>2</sup>), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphomaBrian T Hill, Yanwen Chen, Deepa Jagadeesh, et al.
Hematological Oncology|June 13, 2023
A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapiesRahul Mishra, Danai Dima, Sumukh A Kumar, et al.
Leukemia & Lymphoma|September 15, 2021
The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphomaYazeed Sawalha, Tomas Radivoyevitch, Xuefei Jia, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 6, 2017
Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General PopulationYazan F Madanat, Lisa Rybicki, Tomas Radivoyevitch, et al.
Pageof 10